La vendita allo scoperto per NovoCure dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NovoCure. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NovoCure (NASDAQ:NVCR) Azioni, Report sulle vendite allo scoperto

NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

Raymond James analyst Dane Leone maintains Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) with a Outperform and lowers the price target from $6 to $4.

News

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $4

Barclays analyst Tom O'Malley maintains Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) with a Overweight and raises the price target from $85 to $105.

COHR

Barclays Maintains Overweight on Coherent, Raises Price Target to $105

WIIM

Okeanis Eco Tankers shares are trading lower. The company reported Q3 financial results.

Raymond James analyst Ric Prentiss maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Outperform and raises the price target from $11 to $12.

Raymond James Maintains Outperform on Warner Bros. Discovery, Raises Price Target to $12

Barclays analyst Tim Long maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Overweight and raises the price target from $341 to $495.

ANET

Barclays Maintains Overweight on Arista Networks, Raises Price Target to $495

Raymond James analyst David Feaster reiterates VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) with a Outperform and raises the price target from $15 to $17.

Reiteration

VBNK

Raymond James Reiterates Outperform on VersaBank, Raises Price Target to $17

Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) is betting big on its upcoming Gravity SUV to capture a broader slice of the electric vehicle (EV) market, but it's a <a href="https://www.benzinga.com/quote/LCID/news">cautious play for investors</a>. 
Needham's Chris Pierce reaffirmed a Hold rating on LCID stock, highlighting promising delivery gains while flagging concerns over long-term profitability and further dilution risks.
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Lucid&#8217;s Rising Deliveries, Falling Margins</h2>
Lucid's latest earnings report spotlighted a third consecutive quarter of record deliveries, a rare positive amid the fierce EV competition. The company is using pricing adjustments to fuel this demand, but Pierce noted that discounts have chipped away at the average selling price for five straight quarters.
Despite these pricing moves, Lucid still hasn't cracked the code to profitability—a challenge, as EV giants with delivery volumes five times higher still struggle to achieve positive gross margins, the analyst said.
Read Also: <a href="https://www.benzinga.com/24/11/41838253/lucid-rises-nearly-5-in-pre-market-after-strong-q3-results-opening-orders-for-gravity-suv">Lucid Rises Nearly 5% In Pre-Market After Strong Q3 Results, Opening Orders For Gravity SUV</a>
<h2 class="wp-block-heading">Gravity SUV: A Game Changer Or A Gamble?</h2>
Lucid's Gravity SUV, set for production later this year, represents a significant push to broaden its brand reach. Positioned as Lucid's gateway into the lucrative SUV category, Gravity is expected to expand the company's addressable market. Pierce described it as a "second chance at a first impression" for the brand, although he tempered expectations with a cautious rollout projection, with substantial deliveries not expected until the latter half of 2026.
While Lucid boasts cutting-edge tech that differentiates it from competitors, Pierce noted that the company has yet to achieve strong consumer resonance—a sentiment dampened by slowing EV adoption rates across the industry.
<h2 class="wp-block-heading">The Dilution Dilemma</h2>
Backed by the deep-pocketed Saudi Public Investment Fund (PIF), Lucid has managed to secure substantial funding for its ambitious roadmap. 
However, Pierce foresees additional capital raises—potentially up to $4 billion—necessary to bridge the gap to profitability and push Gravity into the market. For shareholders, this could spell further dilution, with Lucid already leaning on a recent $1.75 billion raise to power through the SUV launch and into 2026, the analyst noted.
<h2 class="wp-block-heading">LCID Chart: The Bulls Hold Out Hope</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122427/Screenshot-2024-11-08-at-10.54.09-PM.png" alt="" class="wp-image-638165" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122427/Screenshot-2024-11-08-at-10.54.09-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122427/Screenshot-2024-11-08-at-10.54.09-PM-300x216.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
Lucid's stock has recently been trading below key moving averages, with the eight, 20-day, and 50-day simple moving averages (SMA) all signaling a bearish trend. The MACD indicator is reinforcing the bearish momentum at a negative 0.29, signaling short-term pessimism.
With the Relative Strength Index (RSI) in oversold territory at 27.17, caution is warranted as investors assess Lucid's extended path to profitability.
Lucid may be cruising forward with promising delivery numbers and an enticing new SUV, but as Needham's Pierce advises, the road to profitability remains long and uncertain. 
For now, it's a waiting game as investors weigh the allure of Lucid's Gravity against the gravitational pull of profitability challenges and potential dilution.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41826774/lucid-q3-earnings-revenue-beat-eps-beat-on-track-to-produce-9k-vehicles-in-2024">Lucid Q3 Earnings: Revenue Beat, EPS Beat, On Track To Produce 9K Vehicles In 2024</a></li>
</ul>
Photo by Mike Mareen on Shutterstock

Analyst Color

Long Ideas

Technicals

Tech

Trading Ideas

LCID

Lucid's Delivery Gains, New SUV Can't Shake Profit Concerns

Raymond James analyst Rick Patel reiterates Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and raises the price target from $55 to $57.

Raymond James Reiterates Outperform on Tapestry, Raises Price Target to $57

Barclays analyst Raimo Lenschow maintains Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) with a Underweight and raises the price target from $29 to $34.

APPN

Barclays Maintains Underweight on Appian, Raises Price Target to $34

<ul>
<li>Data continues positive trend as additional patients are enrolled in 3 cohorts</li>
<li>Vaccine was safe and well tolerated by participants in all 3 cohorts</li>
<li>Protocol defined immune responses were exhibited in over 70% of patients</li>
<li>A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025</li>
</ul>
SAN JOSE, Calif., Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4297993-1&amp;h=2144968050&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04674306&amp;a=NCT04674306">NCT04674306</a>) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense. The presentation, titled "Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC," was presented by Dr. Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic.&nbsp;

Biotech

General

ANIX

Anixa Biosciences And Cleveland Clinic Present New Updated Data From Phase 1 Study Of Breast Cancer Vaccine At The 39th SITC Annual Meeting; Protocol Defined Immune Responses Were Exhibited In Over 70% Of Patients

Barclays analyst Betty Jiang maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Equal-Weight and lowers the price target from $30 to $27.

Barclays Maintains Equal-Weight on APA, Lowers Price Target to $27

RBC Capital analyst Rishi Jaluria maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $250 to $275.

VEEV

RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $275

Barclays analyst Mario Lu maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and raises the price target from $100 to $110.

ABNB

Barclays Maintains Underweight on Airbnb, Raises Price Target to $110

<a href="https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3" title="https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3">https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3</a>

Legal

OTTR

'DoJ Investigates Potential Price-Fixing In PVC Pipe Market' - Financial Times

Editor&#8217;s note: This story has been updated with additional comments tweeted by Bill Ackman. 
Billionaires are lining up to serve in President-elect Donald Trump&#8216;s <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">incoming administration</a>, especially those eager to <a href="https://www.benzinga.com/news/24/08/40146910/does-donald-trumps-proposed-tax-cut-threaten-social-security-and-medicare-heres-what-think-tanks-war">cut federal assistance programs</a>.
Bill Ackman is one of them. 
On Friday morning, when a user on X asked whether the Pershing Square Capital founder would &#8220;consider joining Elon [Musk] in the Department of Government Efficiency,&#8221; Ackman <a href="https://x.com/BillAckman/status/1854891084381377017">replied</a> with a single word: &#8220;Yes.&#8221;
Musk has proposed the idea of creating a &#8220;Department of Government Efficiency.&#8221; This hypothetical agency would slash federal spending by the trillions. Should such a plan come to fruition, analysts suggest programs like health care, food security and housing <a href="https://www.benzinga.com/startups/24/11/41750727/kevin-oleary-supports-elon-musks-2-trillion-plan-to-slash-government-spending-with-trumps-backing-it">would be gutted</a>. 
Trump was receptive to this idea. 
See Also: <a href="https://www.benzinga.com/news/24/07/39657200/ex-trump-staffer-shares-texts-to-prove-that-ex-presidents-campaign-settled-to-keep-discrimination-an">Ex-Trump Staffer Shares Texts To Prove That Ex-President&#8217;s Campaign Settled To Keep Sexual Harassment Lawsuits Quiet</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yes
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1854891084381377017?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ackman is among Trump&#8217;s most ardent Wall Steet supporters. The billionaire told CNBC that he&#8217;s unfazed by the <a href="https://www.benzinga.com/government/24/11/41828468/trump-says-hed-replace-income-taxes-with-tariffs-the-potential-economic-fallout">potential market implications</a> of a second Trump administration.
In a follow-up tweet, Ackman said he is not leaving his day job for one with the Trump administration.
&#8220;Like Elon Musk who has a half a dozen full-time jobs, I would be delighted to help anyway that I can to help DOGE succeed,&#8221; Ackman tweeted. 
Musk contributed nine-digit sums to Trump&#8217;s campaign and organized much of Trump&#8217;s ground game.
The Tesla Inc. CEO has also openly said Americans will experience &#8220;temporary hardship&#8221; once federal cuts are made.
According to the U.S. Treasury, the country&#8217;s federal budget was $6.75 trillion in 2024. Musk&#8217;s proposal to make large cuts to the federal budget would necessitate shedding several categories. Analysts put social security, military spending, Medicare, and veterans benefits on that list.
It remains to be seen how high of a legislative priority this will be for Trump.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41843182/fed-cuts-rates-but-inflation-remains-elephant-in-the-room">Fed Cuts Interest Rates, But Inflation Remains Elephant In The Room</a></li>
</ul>
Image: Shutterstock

Government

Health Care

Politics

Bill Ackman Says He'd Consider Joining Elon Musk's 'Department Of Government Efficiency' Under Trump (UPDATED)

XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares are trading relatively flat on Friday after the company <a href="https://www.benzinga.com/pressreleases/24/11/g41841998/xpeng-unveils-the-p7-worlds-first-ai-defined-vehicle-redefining-premium-and-intelligent-driving">hosted its XPENG AI Day event.</a>
According to&nbsp;<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, XPEV stock has lost over 11% in the past year. Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Kensho Smart Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>).
On November 7, the company officially launched the XPENG P7+, <a href="https://www.benzinga.com/pressreleases/24/11/g41843762/xpeng-unveils-kunpeng-super-electric-system-and-ai-defined-mobility-innovations-at-xpeng-ai-day">the world&#8217;s first AI-defined vehicle, in China.</a>
XPeng has also launched the Kunpeng Super Electric System, an advanced 800V high-voltage platform with &#8220;ultra-fast&#8221; charging and AI-powered optimization. 
The system has a 430 km pure electric range and over 1,400 km combined range, with the ability to add 1 km of range per second during charging, per a press release.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/11/41846732/kars-etf-hits-golden-cross-powered-by-tesla-geely-xpeng-li">KARS ETF Hits Golden Cross Powered By Tesla, Geely, Xpeng, Li</a>
XPeng said that the system includes an &#8220;ultra-quiet&#8221; range extender and a battery management system that extends lifespan by 30%.
These apart, XPeng also unveiled major advancements in autonomous driving, flying cars, and AI robotics. The company's Ultra model Robotaxi features L4-level autonomy, Turing chips, and 3,000T of processing power.
The XPeng AEROHT flying car is a modular design with simple controls, set for its first public flight in November and pre-orders in December.
Additionally, XPeng&#8217;s AI Robot Iron, a humanoid robot with over 60 joints, is already in use for internal operations like factories and stores.
Chairman He Xiaopeng highlighted XPeng&#8217;s commitment to AI innovation as a key factor in driving future mobility.
Price Action: XPEV shares are trading lower by 0.11 to $14.21 at last check Friday.
Photo by Koshiro K on Shutterstock
Read Also:&nbsp;
<a href="https://www.benzinga.com/news/24/01/36508540/what-does-gms-electric-future-look-like-after-chevrolet-bolts-exit-last-years-delivery-numbers-could" target="_blank" rel="noreferrer noopener">What Does GM's Electric Future Look Like After Chevrolet Bolt's Exit? Last Year's Delivery Numbers Could Give A Hint</a>

Equities

Markets

Movers

HAIL

XPEV

What's Going On With XPeng Stock Friday?

Raymond James analyst Brian Peterson maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Strong Buy and lowers the price target from $52 to $50.

Raymond James Maintains Strong Buy on RingCentral, Lowers Price Target to $50

Barclays analyst Duffy Fischer maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Equal-Weight and raises the price target from $295 to $315.

Barclays Maintains Equal-Weight on Air Products & Chemicals, Raises Price Target to $315

RBC Capital analyst Daniel Perlin maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Sector Perform and raises the price target from $27 to $40.

TOST

RBC Capital Maintains Sector Perform on Toast, Raises Price Target to $40

Raymond James analyst Rick Patel maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $215 to $235.

Raymond James Maintains Outperform on Ralph Lauren, Raises Price Target to $235

Latest data shows the largest indicative borrow rate increases among liquid option names include: LASER PHOTONICS CORPORATION (LASE) 1053.64% +308....

Largest borrow rate increases among liquid names

NovoCure Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

NovoCure GAAP EPS of -$0.28 beats by $0.05, revenue of $155.09M beats by $11.14M

Novocure (NVCR) announced that Christoph Brackmann has been appointed as the company's next Chief Financial Officer CFO . Mr. Brackmann will join N...

Novocure appoints Christoph Brackmann as Chief Financial Officer

Novocure appoints Moderna's exec Christoph Brackmann as CFO

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on NovoCure (NVCR – Research Report), with a price target of ...

Strong Financial Performance and Promising Growth Drive Buy Rating for NovoCure

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript

NovoCure Ltd. ( ($NVCR) ) has realeased its Q3 earnings. Here is a breakdown of the information NovoCure Ltd. presented to its investors. Novocure ...

Novocure's Q3 2024 Results Highlight Growth and Innovation

Executive reshuffles: BIIB, USB and WES

ALTM

ARVN

AXTA

BASFY

BIIB

BLKB

BPMC

BYND

COCO

CRMD

CRTO

CVEO

CWEN

EADSF

ENIC

EXTR

FLEX

FVRR

GEHC

GRMN

HESM

INMD

ITCI

IVPAF

LASE

LKNCY

MRNA

NAVI

NBIX

NVCR

OMCL

OPCH

OTIS

PLNT

PSNY

PSNYW

PUMP

ROCK

SIMO

Press Releases

Novocure Reports Second Quarter 2024 Financial Results

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

Novocure Announces Planned CEO Transition

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Novocure to Report Third Quarter 2024 Financial Results

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Comments

NovoCure

Vendite allo scoperto

NovoCure (NASDAQ:NVCR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO